Gastrointestinal Stent Market Size and Share
Gastrointestinal Stent Market Analysis by Mordor Intelligence
The gastrointestinal stent market generated USD 587.80 million in 2025 and is projected to reach USD 763.61 million by 2030, reflecting a CAGR of 5.37% over the forecast window. Rising gastrointestinal (GI) cancer prevalence, a decisive clinical pivot toward minimally invasive endoscopy, and sustained advances in stent design—especially biodegradable and drug-eluting formats—anchor this expansion. Broader use of endoscopic ultrasound (EUS) and artificial-intelligence–guided planning has lowered technical barriers, improved patient-specific customization, and widened procedural suitability, especially for complex pancreaticobiliary disease. North America maintains volume leadership, yet high incidence of colorectal cancer and rapidly modernizing hospital networks position Asia-Pacific as the fastest-advancing region. Robust clinical evidence highlighting cost savings, shorter recovery times, and high patency levels reinforces payer acceptance and accelerates adoption across both malignant and benign indications.
Key Report Takeaways
- By product type, biliary stents led with 37.23% revenue share in 2024; colonic stents are forecast to expand at an 8.94% CAGR through 2030.
- By material, self-expanding metal stents accounted for 61.67% of the gastrointestinal stent market size in 2024, while biodegradable and drug-eluting stents are projected to grow at an 8.79% CAGR to 2030.
- By application, biliary disease captured 41.46% of the gastrointestinal stent market size in 2024, and colorectal cancer applications are advancing at a 9.23% CAGR through 2030.
- By end user, hospitals held 64.55% of the gastrointestinal stent market share in 2024; ambulatory surgical centers are set to rise at a 7.89% CAGR over the forecast period.
- By geography, North America dominated with 35.47% of 2024 revenues, while Asia-Pacific is poised for the fastest 8.23% CAGR through 2030.
Global Gastrointestinal Stent Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Rising prevalence of GI cancers | +1.2% | Global, highest in APAC | Long term (≥ 4 years) |
Ageing population & comorbid GI disorders | +0.8% | North America & EU, expanding to APAC | Long term (≥ 4 years) |
Shift toward minimally invasive endoscopy | +1.5% | Global, led by developed markets | Medium term (2-4 years) |
Rapid adoption of EUS-guided stenting | +0.9% | North America & EU, emerging in APAC | Medium term (2-4 years) |
AI-driven stent design & customization | +0.6% | North America & EU core markets | Long term (≥ 4 years) |
Technological advancement in biodegradable stents | +0.7% | Global, early uptake in developed markets | Long term (≥ 4 years) |
Source: Mordor Intelligence
Rising Prevalence of GI Cancers
Colorectal cancer incidence in Asia climbed to 23.88 per 100,000 population in 2024, overtaking stomach cancer as the dominant GI malignancy and creating sustained demand for colonic stents as bridge-to-surgery aids. Self-expandable metal stents now achieve 89.7% clinical success for malignant gastric outlet obstruction, delivering durable patency and fewer emergency surgeries.[1]Mark Gromski et al., “Endoscopic Stenting for Palliation of Intra-Abdominal Gastrointestinal Malignant Obstruction,” European Journal of Gastroenterology & Hepatology, journals.lww.comIntegration of neoadjuvant chemotherapy with stent placement optimizes tumor shrinkage and surgical outcomes, further strengthening procedure volumes. Broadening cancer screening initiatives coupled with improved survival rates sustains procedure frequency into follow-up and palliative contexts.
Ageing Population & Comorbid GI Disorders
Demographic ageing increases benign biliary strictures and pancreatitis-related complications, conditions often unsuitable for open surgery. Short fully covered metal stents resolve 99% of benign strictures in older cohorts, while lowering procedural risk and hospital stay relative to surgery.[2]Zhi Li et al., “A Short Fully Covered Self-Expandable Metal Stent for Management of Benign Biliary Stricture,” Journal of Clinical Medicine, mdpi.comEnhanced anti-migration features address fragile tissue architecture common in geriatric patients. Health systems seeking value-based care favor these minimally invasive routes, reinforcing long-term utilization across mature markets.
Shift Toward Minimally Invasive Endoscopy
Cost-effectiveness, faster recovery, and broader patient eligibility underpin the move from open surgery to endoscopic alternatives. Boston Scientific’s WallFlex and Epic platforms showcase delivery-system refinements that simplify navigation of tortuous anatomy, heightening procedural safety. Guideline-based training from the European Society of Gastrointestinal Endoscopy standardizes competencies and accelerates technology diffusion.
Rapid Adoption of EUS-Guided Stenting
EUS-guided biliary drainage yields 90% success when conventional ERCP fails, broadening options for patients with surgically altered anatomy.[3]Mohamed Abdel-Wahab et al., “The Role of Endoscopic Ultrasound in Detecting Common Bile Duct Stones,” Egyptian Journal of Internal Medicine, ejim.springeropen.com Purpose-built lumen-apposing metal stents achieve 100% technical success for pancreatic fluid collections, slashing morbidity and hospital days. Investments in simulation-based curricula shorten learning curves and hasten clinical deployment.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Device-related adverse events & re-interventions | −0.7% | Global, higher impact in emerging markets | Short term (≤ 2 years) |
Stringent multi-region regulatory pathways | −0.5% | Global, affects new entrants | Medium term (2-4 years) |
Reimbursement gaps in emerging markets | −0.9% | APAC, Latin America, MEA | Medium term (2-4 years) |
Nitinol supply-chain volatility & price spikes | −0.6% | Global manufacturing impact | Short term (≤ 2 years) |
Source: Mordor Intelligence
Device-Related Adverse Events & Re-Interventions
FDA reports list stent positioning issues (35.6%) and migration events (12.4%) as leading device complaints, with hemorrhage and perforation topping patient-related events. Migration rates can approach 40%, raising cost and patient-safety concerns. Forgotten plastic biliary stents increase cholangitis risk and clogging incidents, prompting calls for automated retrieval reminders. Next-generation anti-migration fins and biodegradable formats aim to cut secondary procedures and enhance quality metrics.
Stringent Multi-Region Regulatory Pathways
Manufacturers face divergent evidence standards across the United States, European Union, and major Asian markets, lengthening approval timelines and escalating trial costs. Harmonization efforts such as EU Medical Device Regulation (MDR) raise documentation requirements, challenging small entrants without extensive compliance infrastructure.
Segment Analysis
By Product Type: Biliary Stents Lead Clinical Applications
Biliary stents held 37.23% share of 2024 revenues in the gastrointestinal stent market, reflecting their entrenched role in malignant and benign biliary obstructions. Laser-cut geometries, hydrophilic coatings, and low-profile delivery catheters foster accurate placement in narrowed ducts and complex hilar lesions. Esophageal and duodenal stents follow in volume, benefitting from improved anti-reflux valves that enhance dysphagia relief.
Colonic stents supply the fastest 8.94% CAGR through 2030. Comparative studies show self-expandable metal stents deliver survival and quality-of-life outcomes on par with emergent surgery while avoiding colostomy formation. Pancreatic designs without internal flaps record 80.7% spontaneous migration, sparing retrieval procedures and aligning with outpatient protocols. Drug-eluting refinements now target tissue in-growth inhibition, signaling new value propositions across all product classes.
Note: Segment shares of all individual segments available upon report purchase
By Material: Self-Expanding Metal Dominance Challenged by Innovation
Self-expanding metal devices captured 61.67% of 2024 revenue, underlining their balance of radial strength and flexibility. Clinical trials confirm 100% technical success for ileocecal obstruction and 92.3% clinical success, validating adaptability outside the traditional left-sided colon. Advanced nitinol processing, including laser-cut micro-mesh patterns, improves conformability across tortuous anatomy.
Biodegradable and drug-eluting formats, posting an 8.79% CAGR, answer the call for temporary scaffolding without removal. Iron-based prototypes enhance mechanical reserve while enabling radiopacity tracking. Hybrid constructs bring metallic backbone reliability alongside timed degradation, promising to shift indication boundaries for benign disease management. Plastic remains relevant for short-term drainage when retrieval is planned early, preserving a niche position in the gastrointestinal stent market.
By Application: Biliary Disease Leadership Amid Colorectal Growth
Biliary disease represented 41.46% of 2024 value, supported by strong guideline endorsement and abundant physician experience. Anti-migration flares, enhanced radiopacity, and fully covered designs reduce tumor in-growth and ease subsequent interventions. Italian consensus recommendations underscore precise sizing and stent selection as outcome determinants.
Colorectal cancer indications accelerate at a 9.23% CAGR through 2030 as bridge-to-surgery protocols gain oncologic acceptance. Multidisciplinary boards integrate stents with neoadjuvant regimens, improving resection margins and lowering temporary stoma rates. Emerging research into inflammatory bowel disease strictures sparks demand for tailored diameters and softer radial force profiles, hinting at future micro-niche growth.
Note: Segment shares of all individual segments available upon report purchase
By End User: Hospital Dominance Challenged by Ambulatory Growth
Hospitals controlled 64.55% of 2024 spending, benefiting from anesthesiology, radiology, and critical-care backup fundamental to complex GI interventions. Integrated digital platforms link imaging, AI planning, and post-procedure tracking, reinforcing hospital centrality in high-acuity cases.
Ambulatory surgical centers advance at 7.89% CAGR, aided by slimline delivery systems and conscious-sedation protocols that shorten stays. Specialty clinics flourish in tertiary hubs, offering pancreaticobiliary expertise and high-throughput scheduling. Portable X-ray and intra-procedure ultrasound options expand point-of-care viability, though stringent patient selection remains essential for safe migration away from inpatient settings.
Geography Analysis
North America generated 35.47% of 2024 turnover, buoyed by established reimbursement pathways and deep procedural expertise. Medicare’s defined coverage for GI stenting underpins predictable payment cycles, while manufacturer-driven registries furnish real-world evidence that speeds payer updates. United States centers emphasize multidisciplinary tumor boards integrating stenting, chemotherapy, and surgery, sustaining mature demand. Canada’s universal insurance similarly ensures equitable access, fostering stable baseline volumes.
Asia-Pacific delivers the fastest 8.23% CAGR through 2030, propelled by aging demographics, growing colorectal cancer incidence, and expanded public insurance. China’s hospital upgrade program and regional CRC screening widen procedural addressability. Japan’s super-aged population mandates minimally invasive approaches, while India’s device-marketing code of conduct seeks to balance commercial incentives with ethical outreach. Reimbursement variability and price caps, however, remain decisive adoption throttles, compelling tiered product portfolios targeting affordability.
Europe displays steady mid-single-digit growth underpinned by harmonized MDR frameworks and robust clinical networks. ESGE-standardized training expands operator proficiency, while cross-border data sharing accelerates technology assessment cycles. Latin America and Middle East & Africa constitute emerging arenas; infrastructure expansion and private-sector hospital investment create runway for advanced endoscopy, yet currency volatility and fragmented insurance dampen immediate penetration.

Competitive Landscape
Market structure skews toward moderate concentration, with Boston Scientific, Cook Medical, and Olympus leveraging broad GI portfolios, extensive service networks, and acquisition-driven scale. Boston Scientific’s USD 1.26 billion Silk Road Medical deal expands neurovascular crossover know-how into GI delivery-system innovations. Teleflex’s €760 million purchase of Biotronik’s vascular unit signals intent to deepen material science capabilities and adjacent access technology.
Innovation wars dominate strategic focus. Merit Medical’s WRAPSODY cell-impermeable endoprosthesis achieved 70.1% patency versus 41.6% standard of care, underlining performance-driven product differentiation. Start-ups commercializing 3D-printed personalized stents promise anatomically exact flare diameters and optimized radial force, though scalability and regulatory evidence remain hurdles.
Supply security and price pressures spur vertical collaboration. OEMs cultivate secondary nitinol sources and adopt laser sintering to internalize component builds, buffering geopolitical supply shocks. Digital service layers—cloud-based planning software, remote proctoring, and AI-driven sizing engines—emerge as stickiness levers, complementing hardware margins and entrenching vendor–provider ecosystems within the gastrointestinal stent industry.
Gastrointestinal Stent Industry Leaders
-
Boston Scientific Corporation
-
Becton Dickinson and Company
-
Cook Medical
-
Abbott
-
Medtronic
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- May 2024: SafeGuard Surgical received FDA breakthrough designation for its LeakGuard biodegradable stent.
- January 2024: Olympus completed the acquisition of Taewoong Medical, adding metallic GI stents to its EndoTherapy line.
Global Gastrointestinal Stent Market Report Scope
As per the scope of the report, gastrointestinal stents are used for the management of obstructive symptoms in the GI tract, which can arise due to diseases of the GI tract, such as malignancies of the stomach, esophagus, duodenum, and pancreas. The Gastrointestinal Stent Market is segmented by Product Type (Biliary Stent, Colonic Stent, Duodenal Stent, Esophageal Stent, and Pancreatic Stent), Application (Biliary Disease, Colorectal Cancer, Stomach Cancer, Inflammatory Bowel Disease, Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
By Product Type | Biliary Stent | ||
Esophageal Stent | |||
Duodenal Stent | |||
Colonic Stent | |||
Pancreatic Stent | |||
By Material | Self-Expanding Metal Stent (SEMS) | ||
Plastic Stent | |||
Biodegradable / Drug-eluting Stent | |||
By Application | Biliary Disease | ||
Colorectal Cancer | |||
Stomach Cancer | |||
Inflammatory Bowel Disease | |||
Other Applications | |||
By End User | Hospitals | ||
Ambulatory Surgical Centers | |||
Specialty Clinics | |||
By Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Biliary Stent |
Esophageal Stent |
Duodenal Stent |
Colonic Stent |
Pancreatic Stent |
Self-Expanding Metal Stent (SEMS) |
Plastic Stent |
Biodegradable / Drug-eluting Stent |
Biliary Disease |
Colorectal Cancer |
Stomach Cancer |
Inflammatory Bowel Disease |
Other Applications |
Hospitals |
Ambulatory Surgical Centers |
Specialty Clinics |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia-Pacific | China |
Japan | |
India | |
Australia | |
South Korea | |
Rest of Asia-Pacific | |
Middle East and Africa | GCC |
South Africa | |
Rest of Middle East and Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
1. What is the current size of the gastrointestinal stent market?
The market generated USD 587.80 million in 2025 and is forecast to climb to USD 763.61 million by 2030 at a 5.37% CAGR.
2. Which product category holds the largest share?
Biliary stents lead with 37.23% revenue share due to their central role in managing malignant and benign biliary obstructions.
3. Why are biodegradable stents gaining traction?
Biodegradable designs eliminate retrieval procedures, reduce long-term adverse events, and are projected to grow at an 8.79% CAGR, the fastest among material
4. Which region is expanding the fastest?
Asia-Pacific shows the highest 8.23% CAGR, driven by rising colorectal cancer incidence, healthcare infrastructure upgrades, and broader insurance coverage.
5. What are the main clinical drivers for market growth?
Key growth factors include increasing GI cancer prevalence, ageing populations with comorbidities, rapid uptake of EUS-guided techniques, and ongoing shifts toward minimally invasive endoscopy.
Page last updated on: June 21, 2025